These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 23956442)
1. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442 [TBL] [Abstract][Full Text] [Related]
2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival]. Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767 [No Abstract] [Full Text] [Related]
3. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. Omae K; Kondo T; Kennoki T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K Int J Clin Oncol; 2016 Feb; 21(1):126-32. PubMed ID: 26163345 [TBL] [Abstract][Full Text] [Related]
4. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172 [TBL] [Abstract][Full Text] [Related]
5. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Zhang HL; Qin XJ; Wang HK; Gu WJ; Ma CG; Shi GH; Zhou LP; Ye DW Oncotarget; 2015 Nov; 6(34):36870-83. PubMed ID: 26472104 [TBL] [Abstract][Full Text] [Related]
8. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study. Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma. Zhang Y; Li Y; Cai Y; Wang K; Li H Cell Oncol (Dordr); 2016 Feb; 39(1):15-21. PubMed ID: 26597814 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma. Sil A; Das NK Indian J Pharmacol; 2014; 46(3):334-6. PubMed ID: 24987183 [TBL] [Abstract][Full Text] [Related]
12. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640 [TBL] [Abstract][Full Text] [Related]
13. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance. Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897 [TBL] [Abstract][Full Text] [Related]
14. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317 [TBL] [Abstract][Full Text] [Related]
15. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Poprach A; Pavlik T; Melichar B; Puzanov I; Dusek L; Bortlicek Z; Vyzula R; Abrahamova J; Buchler T; Ann Oncol; 2012 Dec; 23(12):3137-3143. PubMed ID: 22700990 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib. Kondo T; Nakazawa H; Oya M; Kimura G; Fujii Y; Hatano T; Kawata N; Kume H; Morita M; Nakajima K; Ohno Y; Okegawa T; Takahashi S; Wakumoto Y; Horie S; Yamaguchi R; Saito K; Murakami M Jpn J Clin Oncol; 2015 Mar; 45(3):274-80. PubMed ID: 25420693 [TBL] [Abstract][Full Text] [Related]
17. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366 [TBL] [Abstract][Full Text] [Related]
19. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402 [TBL] [Abstract][Full Text] [Related]
20. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report]. Takagi K; Takai M; Kawata K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Ushikoshi H; Miyazaki T; Deguchi T Hinyokika Kiyo; 2015 Sep; 61(9):347-51. PubMed ID: 26497860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]